A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome: a randomised, double-blind, placebo-controlled trial (RECOVERY trial). human fecal metagenome

Post-acute COVID-19 syndrome (PACS) affects at least 65 million individuals worldwide but treatment is limited. Whether microbiota modulation is effective in PACS is unknown. We aimed to assess the efficacy of a novel synbiotic preparation (SIM01) on the alleviation of PACS symptoms.

新冠后急性后遗症（Post-acute COVID-19 syndrome, PACS）在全球范围内至少影响6500万人群，但当前可用治疗手段十分有限。目前，微生物群调控对新冠后急性后遗症是否有效尚不明确。本研究旨在评估一款新型合生制剂（synbiotic preparation, SIM01）缓解新冠后急性后遗症症状的疗效。